Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has provided an announcement.
ResMed Inc. has reported an increase in the number of CHESS Depositary Interests (CDIs) quoted on the ASX for January 2026, with total CDIs on issue rising to 580,546,240 from 579,449,490, a net increase of 1,096,750 driven by net transfers between CDIs and common stock listed on the NYSE. Over the same period, the pool of underlying securities over which CDIs have not been issued fell, reflecting transfers between ASX-quoted CDIs and NYSE-listed shares, new share issuance tied to employee equity plans, and share repurchases on the NYSE, underscoring ongoing capital management activity and routine adjustments to the company’s cross-border share structure.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$53.20 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. is a global medical technology company that develops and manufactures devices and software solutions for the diagnosis, treatment and management of sleep-disordered breathing and other chronic respiratory conditions. The company is dual listed, with common stock traded on the NYSE and CHESS Depositary Interests (CDIs) quoted on the ASX, allowing it to access both U.S. and Australian capital markets.
Average Trading Volume: 1,063,834
Technical Sentiment Signal: Buy
Current Market Cap: A$52.82B
For detailed information about RMD stock, go to TipRanks’ Stock Analysis page.